The complaint, captioned Hu v. Insulet Corporation et al., alleges that the company violated federal securities laws by failing to disclose manufacturing defects. These issues reportedly caused tears in internal tubing, potentially leading to insulin under-delivery or leakage within the pods. The firm Bleichmar Fonti & Auld LLP initiated the action after the company’s stock price experienced significant volatility linked to voluntary medical device corrections.
In section Releases
Insulet Investors Face August 31 Deadline in Securities Fraud Lawsuit
Investors in Insulet Corporation have until August 31, 2026, to seek lead plaintiff status in a class action lawsuit filed in the U.S. District Court for the District of Massachusetts. The litigation follows allegations that the medical device manufacturer misrepresented the safety and manufacturing quality of its Omnipod insulin delivery systems.
On March 12, 2026, Insulet shares fell 6.88% following the disclosure of a defect in specific Omnipod 5 lots. A subsequent correction announced on May 26, 2026, affecting the Omnipod 5, DASH, and Eros systems, triggered a further 5.07% decline. Investors who purchased Insulet securities during the period in question are encouraged to review their legal options through the firm's case portal.
Comments (0)
No comments yet. Be the first!